Biogen, Eisai's BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association International Conference showing that the anti-β-amyloid therapy slowed cognitive decline by as much as 30%. However, inconsistencies in the dose response and an imbalance of high-risk patients across the treatment and placebo arms may have spooked investors, with Biogen falling $45.83 (12%) to $338 in after-hours trading on July 25. The data were presented after market close.

In the Phase II Study

Read the full 806 word article

User Sign In